晚期慢性肾脏病及肾移植后C3差向异构维生素D与心血管结构功能的关系
在CAPER队列165例晚期慢性肾脏病患者中,基线3-epi-25(OH)D3处于最低四分位组(<0.4 ng/mL)的患者峰值氧摄取量低于最高四分位组(≥0.8 ng/mL),组间差异有统计学意义(P=.009)。纵向分析显示3-epi-25(OH)D3水平在肾移植受者中升高、在未移植等待者中下降(P<.001),且与峰值氧摄取量纵向相关,但与左心室质量或动脉僵硬度无关。非差向异构的25(OH)D3、24,25(OH)2D3及其比值与任何心血管结局均无关。
要点
- 基线3-epi-25(OH)D3最低四分位组(<0.4 ng/mL)峰值氧摄取量低于最高四分位组(≥0.8 ng/mL),P=.009。
- 3-epi-25(OH)D3在肾移植受者中升高、在未移植等待者中下降,P<.001;与峰值氧摄取量纵向相关。
- 3-epi-25(OH)D3与左心室质量或动脉僵硬度无关;非差向异构维生素D代谢物与心血管结局均无关。
核心结论
- 3-epi-25(OH)D3水平的变化可能调节晚期慢性肾脏病患者的心血管功能储备。
研究设计与样本
- 研究为CAPER(晚期肾衰竭及肾移植后心肺运动试验)研究队列分析,纳入165例晚期慢性肾脏病患者,其中肾移植受者76例、未移植等待者89例。
- 所有患者在基线、2个月和12个月接受心肺运动试验和超声心动图检查,血清3-epi-25(OH)D3采用液相色谱-串联质谱法检测。
主要发现
- 按基线3-epi-25(OH)D3四分位分组:Q1 <0.4 ng/mL(n=51)、Q2 0.4 ng/mL(n=26)、Q3 0.5-0.7 ng/mL(n=47)、Q4 ≥0.8 ng/mL(n=41)。
- Q1组峰值氧摄取量为18.4(16.2-20.8)mL/min/kg,低于Q4组的20.8(18.6-23.2)mL/min/kg,P=.009。
- 线性混合回归模型显示3-epi-25(OH)D3水平在肾移植受者中从0.47(0.30)ng/mL升高至0.90(0.45)ng/mL,在未移植等待者中从0.61(0.32)ng/mL下降至0.45(0.29)ng/mL,P<.001。
- 3-epi-25(OH)D3与峰值氧摄取量纵向相关:肾移植受者β(标准误)=2.53(0.56),P<.001;未移植等待者β(标准误)=2.73(0.70),P<.001。
- 3-epi-25(OH)D3与左心室质量或动脉僵硬度无关;非差向异构25(OH)D3、24,25(OH)2D3及25(OH)D3:24,25(OH)2D3比值与任何心血管结局均无关(所有P>.05)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: 25-hydroxyvitamin D can undergo C-3 epimerization to produce 3-epi-25(OH)D3. 3-epi-25(OH)D3 levels decline in chronic kidney disease (CKD), but its role in regulating the cardiovascular system is unknown. Herein, we examined the relationship between 3-epi-25(OH)D3, and cardiovascular functional and structural endpoints in patients with CKD. METHODS: We examined n = 165 patients with advanced CKD from the Cardiopulmonary Exercise Testing in Renal Failure and After Kidney Transplantation (CAPER) study cohort, including those who underwent kidney transplant (KTR, n = 76) and waitlisted patients who did not (NTWC, n = 89). All patients underwent cardiopulmonary exercise testing and echocardiography at baseline, 2 months and 12 months. Serum 3-epi-25(OH)D3 was analyzed by liquid chromatography-tandem mass spectrometry. RESULTS: Patients were stratified into quartiles of baseline 3-epi-25(OH)D3 (Q1: <0.4 ng/mL, n = 51; Q2: 0.4 ng/mL, n = 26; Q3: 0.5-0.7 ng/mL, n = 47; Q4: ≥0.8 ng/mL, n = 41). Patients in Q1 exhibited lower peak oxygen uptake [VO2Peak = 18.4 (16.2-20.8) mL/min/kg] compared with Q4 [20.8 (18.6-23.2) mL/min/kg; P = .009]. Linear mixed regression model showed that 3-epi-25(OH)D3 levels increased in KTR [from 0.47 (0.30) ng/mL to 0.90 (0.45) ng/mL] and declined in NTWC [from 0.61 (0.32) ng/mL to 0.45 (0.29) ng/mL; P < .001]. Serum 3-epi-25(OH)D3 was associated with VO2Peak longitudinally in both groups [KTR: β (standard error) = 2.53 (0.56), P < .001; NTWC: 2.73 (0.70), P < .001], but was not with left ventricular mass or arterial stiffness. Non-epimeric 25(OH)D3, 24,25(OH)2D3 and the 25(OH)D3:24,25(OH)2D3 ratio were not associated with any cardiovascular outcome (all P > .05). CONCLUSIONS: Changes in 3-epi-25(OH)D3 levels may regulate cardiovascular functional capacity in patients with advanced CKD.
引用
- Arroyo E, Leber CA, Burney HN, et al. Epimeric vitamin D and cardiovascular structure and function in advanced CKD and after kidney transplantation. Nephrol Dial Transplant. 2024. PMID: 37468453. doi:10.1093/ndt/gfad168
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。